Harnessing Data to Build More Inclusive Clinical Trials

Diversity in clinical trials is not just a regulatory box to check — it’s an ethical imperative and a scientific necessity. Ensuring that clinical studies are inclusive of all populations affected by a disease is crucial for developing treatments that are safe and effective for everyone.

As the healthcare industry continues to recognize the significance of diversity, tools and strategies are emerging to better address these challenges. To gain more insights into the evolving strategies that are helping to make clinical trials more inclusive, Xtalks spoke with Ryan Brown, Regional Vice President of Sales for Trial Landscape at H1.

Brown shared her insights on how incorporating diversity from the outset can enhance the scientific validity of trials and ensure that the benefits of new therapies are accessible to all segments of the population. Her thoughts offer a valuable perspective on the ongoing efforts to improve the inclusivity of clinical research on a global scale.

A Holistic Approach to Diversity in Clinical Trials

Achieving true diversity in clinical trials requires a comprehensive, 360-degree approach that considers a variety of factors, including but not limited to race and gender. Ryan Brown emphasizes that “it’s an imperative to think globally and act locally, especially when we’re considering the holistic view of diversity.”

This approach begins with a deep understanding of the disease epidemiology—who is most affected by the condition, and how does it manifest in different populations? By starting with this foundational knowledge, researchers can identify which populations need to be prioritized in the trial design to ensure that the study results are both meaningful and applicable to those most impacted by the disease.

Diversity is not a one-size-fits-all concept. It varies significantly depending on the region, the disease state and the regulatory environment. For example, in one region, diversity might focus on ethnic representation, while in another, it might center around age or socioeconomic status. This understanding necessitates a tailored approach to each trial, ensuring that the unique aspects of diversity in each context are carefully considered and addressed.

Beyond traditional demographic factors, social determinants of health (SDOH) like transportation, financial stability and language barriers play a critical role in patient participation. Incorporating SDOH data into trial planning ensures that studies are more inclusive and accessible to diverse populations.

Collaboration is also key to a holistic approach. Brown underscores the importance of engaging local partners and communities, stating that “we need to leverage data to inform where we’re going to go and who we should collaborate with.” Involving local investigators and patient advocacy groups from the outset helps align trial designs with the needs of participants.

Additionally, Brown emphasizes the importance of ongoing engagement and validation at the local level. This means going beyond initial planning to continually engage with sites, study coordinators and patients throughout the trial. By doing so, researchers can ensure that the study remains aligned with the needs and realities of the participants, leading to more successful and inclusive outcomes. This iterative process of planning, collaboration and validation is crucial for making clinical trials truly reflective of the diverse populations they aim to serve.